WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013119040) COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/119040    International Application No.:    PCT/KR2013/000954
Publication Date: 15.08.2013 International Filing Date: 06.02.2013
IPC:
C07D 471/04 (2006.01), A61K 31/437 (2006.01), A61P 3/00 (2006.01)
Applicants: KAINOS MEDICINE, INC. [KR/KR]; 11F, Asan Institute for Life Sciences, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736 (KR)
Inventors: KIM, Dooseop; (KR).
BOK, Juhan; (KR).
SHIN, Sunmi; (KR)
Agent: FIRSTLAW P.C.; Trust Tower 275-7 Yangjae-Dong, Seocho-Ku Seoul 137-739 (KR)
Priority Data:
61/595,796 07.02.2012 US
Title (EN) COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME
(FR) COMPOSÉS COMME INHIBITEURS DE L'ENZYME DIACYLGLYCÉROL O-ACYLTRANSFÉRASE DE TYPE 1
Abstract: front page image
(EN)The invention provides a novel compound having activity against diacylglycerol O-acyltransferase type 1 (DGAT1); a pharmaceutical composition for preventing or treating a disease, disorder or condition modulated by inhibition of DGAT1 comprising said compound; a method for preventing or treating a disease, disorder or condition modulated by inhibition of DGAT1 in an individual comprising administering said compound to the individual in need thereof; and a use of said compound for the manufacture of a medicament for preventing or treating a disease, disorder or condition modulated by DGAT1 inhibition.
(FR)La présente invention concerne un nouveau composé possédant une activité contre la diacylglycérol O-acyltransférase de type 1 (DGAT1) ; une composition pharmaceutique permettant de prévenir ou de traiter une maladie, un trouble ou un état modulé par l'inhibition de la DGAT1 comprenant ledit composé ; un procédé permettant de prévenir ou de traiter une maladie, un trouble ou un état modulé par l'inhibition de la DGAT1 chez un individu consistant à administrer ledit composé à l'individu en ayant besoin ; et une application dudit composé pour la fabrication d'un médicament permettant de prévenir ou de traiter une maladie, un trouble ou un état modulé par l'inhibition de la DGAT1.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)